G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

Trilaciclib Reduces Hospitalizations and Myelosuppressive Events in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) and May Improve Survival

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology (ASCO) small cell lung cancer (SCLC) guidelines for patients with untreated or previously treated extensive-stage small cell lung cancer (ES-SCLC) who are undergoing treatment with chemotherapy or chemoimmunotherapy.

G1 Therapeutics' COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m.

G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA.

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants William Roberts - VP, IR & Corporate Communications John Bailey - CEO, President & Director Andrew Perry - Chief Commercial Officer Rajesh Malik - Chief Medical Officer John Umstead - CFO Conference Call Participants Gil Blum - Needham & Company Kaveri Pohlman - BTIG Anupam Rama - JPMorgan Chase & Co. Troy Langford - TD Cowen Operator Good day, and thank you for standing by. Welcome to the G1 Second Quarter Financial Results Conference Call.

G1 Therapeutics, Inc. (GTHX) Q2 2023 Earnings Call Transcript

G1 Therapeutics (GTHX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to loss of $0.92 per share a year ago.

G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA® (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Presented New Phase 2 Results Confirming Benefit of Trilaciclib in Reducing Adverse Events Associated with an Antibody-Drug Conjugate (ADC) in Triple Negative Breast Cancer (TNBC) - - Provided Phase 2 Mechanism of Action Trial Results Clarifying Trilaciclib's Role in Enhancing Immune Surveillance and Efficacy as Measured by Long Term Endpoints like Overall Survival (OS) - - Improved Financial Strength By Amending Hercules Debt Facility and Receiving Payment from Simcere for Relief of Future Royalties; Cash Runway Extends Beyond Expected Clinical Trial Readouts in Early 2024 - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Aug. 02, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2023.

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences.

G1 Therapeutics to Participate in Two August Investor Conferences

- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events (HAEs) Including Neutropenia, Anemia, and Thrombocytopenia -

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the second quarter 2023 on Wednesday August 2, 2023, at 8:30 a.m. ET.

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

Day One Biopharmaceuticals

Evaxion Biotech A/S

ImmunoGen

Shares of several cancer drug firms surged on Monday after the companies reported positive clinical trial data from their therapies at an ongoing industry conference in Chicago.

Cancer drugmakers rise as industry meet fuels investor interest

- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microenvironment -

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the Appointment The Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) in Conjunction with the Appointment

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

GTHX halted the CRC trial on low survival benefits. There are reasons its other trials with trilaciclib could be more positive.

G1 Therapeutics: Without Cash, The CRC Failure Becomes A Tougher Hurdle

Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

- On-Target Effect of Trilaciclib Reduces Rates of Multiple Adverse Events Associated with Sacituzumab Govitecan-Hziy by Over 50% Including Neutropenia, Anemia, and Diarrhea -

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2023 Earnings Conference Call May 3, 2023 8:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry - Chief Commercial Officer Raj Malik - Chief Medical Officer John Umstead - Chief Financial Officer Conference Call Participants Gil Blum - Needham & Company Ed White - H.C. Wainwright Dane Leone - Raymond James Troy Langford - TD Cowen David Nierengarten - Wedbush Securities Kaveri Pohlman - BTIG Operator Good day and thank you for standing by.

G1 Therapeutics, Inc. (GTHX) Q1 2023 Earnings Call Transcript

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $1.15 per share a year ago.

G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates

- Drove 18% Quarterly Net Revenue Growth of COSELA® (trilaciclib) Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter -

G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter 2023 on Wednesday May 3, 2023, at 8:30 a.m. ET.

G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

G1 Therapeutics (GTHX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

G1 Therapeutics (GTHX) Moves to Buy: Rationale Behind the Upgrade

RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey and other members of the Executive Team will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference. The fireside chat will take place on Tuesday April 18th at 1:30 PM EDT.

G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Despite the recent debacle that clobbered this stock, G1 Therapeutics, Inc. could deliver you more upsides, as it'll likely make a comeback in H2 this year with more data releases. The Phase 3 (PRESERVE 1) trial for colorectal cancer cleared its primary endpoints. Nonetheless, the efficacy data was subpar, which renders further Cosela development for this particular cancer.

News for G1 Therapeutics Stock (GTHX)